Literature DB >> 11479069

Ethical issues in early-intervention clinical trials involving minors at risk for schizophrenia.

D DeGrazia1.   

Abstract

Early-intervention clinical trials involving persons at risk for schizophrenia raise a variety of ethical issues. These issues range from some of the most general questions of ethical theory and research ethics to some very specific pragmatic questions about optimal procedures for protecting subjects. Giving special attention to minor subjects (and adult subjects lacking decision-making capacity), this paper aims to provide an overview of some leading ethical issues and concerns as well as a rights-based framework and several concrete suggestions for addressing these issues and concerns.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11479069     DOI: 10.1016/s0920-9964(01)00243-2

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  8 in total

Review 1.  Emerging empirical evidence on the ethics of schizophrenia research.

Authors:  Laura B Dunn; Philip J Candilis; Laura Weiss Roberts
Journal:  Schizophr Bull       Date:  2005-10-19       Impact factor: 9.306

2.  Defining the Boundaries of a Right to Adequate Protection: A New Lens on Pediatric Research Ethics.

Authors:  David DeGrazia; Michelle Groman; Lisa M Lee
Journal:  J Med Philos       Date:  2017-04-01

Review 3.  Antipsychotic medication for early episode schizophrenia.

Authors:  John Bola; Dennis Kao; Haluk Soydan
Journal:  Cochrane Database Syst Rev       Date:  2011-06-15

Review 4.  Research in people with psychosis risk syndrome: a review of the current evidence and future directions.

Authors:  Christoph U Correll; Marta Hauser; Andrea M Auther; Barbara A Cornblatt
Journal:  J Child Psychol Psychiatry       Date:  2010-02-26       Impact factor: 8.982

5.  Prodromal interventions for schizophrenia vulnerability: the risks of being "at risk".

Authors:  Cheryl Corcoran; Dolores Malaspina; Laura Hercher
Journal:  Schizophr Res       Date:  2005-03-01       Impact factor: 4.939

Review 6.  Cognitive behavioral therapy in prodromal psychosis.

Authors:  Jean Addington; Catherine Marshall; Paul French
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 7.  Prevention of schizophrenia: can it be achieved?

Authors:  Cheng Lee; Thomas H McGlashan; Scott W Woods
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

8.  Schizophrenia proteomics: biomarkers on the path to laboratory medicine?

Authors:  Shaheen Emmanuel Lakhan
Journal:  Diagn Pathol       Date:  2006-07-17       Impact factor: 2.644

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.